Bio-artificial Kidney: A Silver Bullet in Kidney Transplant and Kidney Diseases
Main Article Content
Abstract
Chronic Kidney Disease (CKD) is a serious health condition that affects millions of people worldwide. Dialysis is the most common treatment for kidney failure, but it has significant drawbacks, including limited effectiveness, frequent sessions, and various complications. Bio-artificial kidney technology has brought new hope to the field of kidney transplantation. This cutting-edge technology aims to revolutionize kidney health by providing a viable solution for individuals suffering from End-stage Renal Disease (ESRD) and reducing their dependence on traditional dialysis methods. This innovative treatment option has the potential to transform the field and improve patient outcomes on a global scale. Moreover, this innovative technology can lead to cost savings, improved patient outcomes, and enhanced healthcare efficiency. In this review, we summarize the current state of the art of kidney disease management and discuss the development and widespread implementation of this innovative treatment technology.
Article Details
Copyright (c) 2025 Ali G, et al.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Kakitapalli Y, Ampolu J, Madasu SD, Sai Kumar MLS. Detailed review of chronic kidney disease. Kidney Dis (Basel). 2020;6(2):85–91. Available from: https://doi.org/10.1159/000504622
Stevens LA, Viswanathan G, Weiner DE. CKD and ESRD in the elderly: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis. 2010;17(4):293–301. Available from: https://doi.org/10.1053/j.ackd.2010.03.010
Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc. 2014;125:229–46. Available from: https://pubmed.ncbi.nlm.nih.gov/25125737/
Murabito S, Hallmark BF. Complications of kidney disease. Nurs Clin North Am. 2018;53(4):579–88. Available from: https://doi.org/10.1016/j.cnur.2018.07.010
Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369(14):1336–43. Available from: https://doi.org/10.1056/nejmra1109345
National Kidney Foundation. Global Facts: About Kidney Disease [Internet]. 2015–2016. Available from: https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease
Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference. Clin J Am Soc Nephrol. 2008;3(2):471–80. Available from: https://doi.org/10.2215/cjn.05021107
Corstorphine L, Sefton MV. Effectiveness factor and diffusion limitations in collagen gel modules containing HepG2 cells. J Tissue Eng Regen Med. 2011;5(2):119–29. Available from: https://doi.org/10.1002/term.296
Cooper TP, Sefton MV. Fibronectin coating of collagen modules increases in vivo HUVEC survival and vessel formation in SCID mice. Acta Biomater. 2011;7(3):1072–83. Available from: https://doi.org/10.1016/j.actbio.2010.11.008
Arenas-Herrera JE, Ko IK, Atala A, Yoo JJ. Decellularization for whole organ bioengineering. Biomed Mater. 2013;8(1):014106. Available from: https://doi.org/10.1088/1748-6041/8/1/014106
Bach LA, Hale LJ. Insulin-like growth factors and kidney disease. Am J Kidney Dis. 2015 Feb;65(2):327–36. Available from: https://doi.org/10.1053/j.ajkd.2014.05.024
Corridon P, Rhodes G, Zhang S, Bready D, Xu W, Witzmann F, et al. Hydrodynamic delivery of mitochondrial genes in vivo protects against moderate ischemia-reperfusion injury in the rat kidney (690.17). FASEB J. 2014;28(1 Suppl):690.17. Available from: http://dx.doi.org/10.1096/fasebj.28.1_supplement.690.17
Ichishita R, Matsuda T, Kawakami S, Kiyonaga A, Tanaka H, Morito N, et al. The accumulation of healthy lifestyle behaviors prevents the incidence of chronic kidney disease (CKD) in middle-aged and older males. Environ Health Prev Med. 2016;21:129–37. Available from: https://doi.org/10.1007/s12199-016-0506-6
Reddenna L, Basha SA, Reddy KSK. Dialysis treatment: a comprehensive description. Int J Pharm Res Allied Sci. 2014;3(1). Available from: https://www.scirp.org/reference/referencespapers?referenceid=1705519
Venkat KK, Eshelman AK. The evolving approach to ethical issues in living donor kidney transplantation: A review based on illustrative case vignettes. Transpl Rev (Orlando). 2014;28(3):134–9. Available from: https://doi.org/10.1016/j.trre.2014.04.001
Basile A, Annesini MC, Piemonte V, Charcosset C, editors. Current Trends and Future Developments on (Bio-) Membranes: Membrane Applications in Artificial Organs and Tissue Engineering. 2019. Available from: https://shop.elsevier.com/books/current-trends-and-future-developments-on-bio-membranes/basile/978-0-12-814225-7
Attanasio C, Latancia MT, Otterbein LE, Netti PA. Update on renal replacement therapy: implantable artificial devices and bioengineered organs. Tissue Eng Part B Rev. 2016;22(4):330–40. Available from: https://doi.org/10.1089/ten.teb.2015.0467
Chevtchik NV, Pinto PC, Masereeuw R, Stamatialis D. Membranes for bioartificial kidney devices. World Sci Ser Membr Sci Technol. 2018;2. Available from: https://research.utwente.nl/en/publications/membranes-for-bioartificial-kidney-devices
Peloso A, Katari R, Murphy SV, Zambon JP, DeFrancesco A, Farney AC, et al. Prospect for kidney bioengineering: shortcomings of the status quo. Expert Opin Biol Ther. 2015;15(4):547–58. Available from: https://doi.org/10.1517/14712598.2015.993376
Duy Nguyen BT, Nguyen Thi HY, Nguyen Thi BP, Kang DK, Kim JF. The roles of membrane technology in artificial organs: current challenges and perspectives. Membranes (Basel). 2021;11(4):239. Available from: https://doi.org/10.3390/membranes11040239
Ostadfar A. Design and experimental proof of selected functions in implantable artificial kidney [dissertation]. 2013. Available from: https://summit.sfu.ca/item/13866
Jansen J, Fedecostante M, Wilmer MJ, van den Heuvel LP, Hoenderop JG, Masereeuw R. Biotechnological challenges of bioartificial kidney engineering. Biotechnol Adv. 2014;32(7):1317–27. Available from: https://doi.org/10.1016/j.biotechadv.2014.08.001
Kellum JA, Bellomo R, Ronco C, editors. Continuous renal replacement therapy. Oxford: Oxford University Press; 2016. Available from: https://academic.oup.com/book/24475
Marques AP. Prospects of tissue engineering in wound management. 2019;3:15. Available from: https://repositorium.uminho.pt/handle/1822/75134
Holmberg JA, Henry SM, Burnouf T, Devine D, Marschner S, Boothby TC, et al. National Blood Foundation 2021 Research and Development summit: Discovery, innovation, and challenges in advancing blood and biotherapies. Transfusion. 2022;62(11):2391–404. Available from: https://doi.org/10.1111/trf.17092
Loai S, Kingston BR, Wang Z, Philpott DN, Tao M, Cheng HLM. Clinical perspectives on 3D bioprinting paradigms for regenerative medicine. Regen Med Front. 2019;1(1):e190004. Available from: https://doi.org/10.20900/rmf20190004
Shapira A, Noor N, Oved H, Dvir T. Transparent support media for high resolution 3D printing of volumetric cell-containing ECM structures. Biomed Mater. 2020;15(4):045018. Available from: https://doi.org/10.1088/1748-605x/ab809f
Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M. The current and future landscape of dialysis. Nat Rev Nephrol. 2020;16(10):573–85. Available from: https://doi.org/10.1038/s41581-020-0315-4
Nagasubramanian S. The future of the artificial kidney. Indian J Urol. 2021;37(4):310–7. Available from: https://doi.org/10.4103/iju.iju_273_21
Bonventre JV, Hurst FP, West M, Wu I, Roy-Chaudhury P, Sheldon M. A technology roadmap for innovative approaches to kidney replacement therapies: a catalyst for change. Clin J Am Soc Nephrol. 2019;14(10):1539–47. Available from: https://doi.org/10.2215/cjn.02570319